Difference between revisions of "Stub"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 708: Line 708:
 
====Growth factor therapy====
 
====Growth factor therapy====
 
*[[Lenograstim (Granocyte)]]
 
*[[Lenograstim (Granocyte)]]
−
====Targeted therapy====
+
====Antibody-drug conjugate therapy====
 
*[[Gemtuzumab ozogamicin (Mylotarg)]]
 
*[[Gemtuzumab ozogamicin (Mylotarg)]]
  

Revision as of 14:58, 28 September 2022

Back to Top

Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the HemOnc Ontology and for historic interest.


Regimens composed solely of approved drugs

3M

3M: Mitomycin, Mitoxantrone, Methotrexate

Regimen

Chemotherapy

5-FU & RT

Regimen

Chemotherapy

Radiotherapy

7+3i & Clofarabine

7+3i & Clofarabine: 7 days of cytarabine, 3 days of idarubicin, Clofarabine

Regimen

Chemotherapy

7+3i & Lenalidomide

7+3i & Lenalidomide: 7 days of cytarabine, 3 days of idarubicin, Lenalidomide

Regimen

Chemotherapy

Targeted therapy

7+4i

7+4i: 7 days of cytarabine, 4 days of idarubicin

Regimen

Chemotherapy

7+5d

7+5d: 7 days of cytarabine, 5 days of daunorubicin

Regimen

Chemotherapy

Abiraterone & Enzalutamide

Regimen

Endocrine therapy

ABVP

Regimen

Chemotherapy

ACP

ACP: Atezolizumab, Carboplatin, Paclitaxel

Regimen

Immunotherapy

Chemotherapy

Afatinib & Vinorelbine

Regimen

Chemotherapy

Targeted therapy

A-ICE

A-ICE: ATRA, Idarubicin, Cytarabine, Etoposide

Regimen

Targeted therapy

Chemotherapy

AME

AME: Ara-C (Cytarabine), Mitoxantrone, Etoposide

Regimen

Chemotherapy

Amsacrine & IDAC

Amsacrine & IDAC: Amsacrine & Intermediate Dose Ara-C (Cytarabine)

Regimen

Chemotherapy

ATRA, Cytarabine, Etoposide

Regimen

Targeted therapy

Chemotherapy

AVML

Regimen

Chemotherapy

Supportive therapy

Binimetinib monotherapy

Regimen

Targeted therapy

Bortezomib & Bevacizumab

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
White et al. 2012 (AMBER) 2007-2009 Randomized Phase 2 (E-esc) Bortezomib Did not meet primary endpoint of PFS
(HR 0.74, 95% CI 0.43-1.28)

Targeted therapy

Bortezomib & Siltuximab

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Orlowski et al. 2015 (CR012784) 2006-2009 Randomized Phase 2 (E-esc) Bortezomib Did not meet primary endpoint of PFS
(HR 0.87, 95% CI 0.65-1.16)

Targeted therapy

BTH (Docetaxel)

BTH: Bevacizumab, Taxotere (Docetaxel), Herceptin (Trastuzumab)

Regimen

Chemotherapy

Targeted therapy

BTOC

BTOC: BCNU, Thiotepa, Oncovin (Vincristine), Cyclophosphamide

Regimen

Chemotherapy

CAD

CAD: Cyclophosphamide, Adriamycin (Doxorubicin), DDP (Cisplatin)

Regimen

Chemotherapy

Capecitabine & Cisplatin (CX) & Bevacizumab

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Cisplatin (CX) & Ramucirumab

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Ruxolitinib

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Sorafenib

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Sunitinib

Regimen

Chemotherapy

Targeted therapy

Capecitabine & Vinflunine

Regimen

Chemotherapy

Capecitabine & Vinorelbine (NX)

NX: Navelbine (Vinorelbine) & Xeloda (Capecitabine)

Regimen

Chemotherapy

Capecitabine, Cisplatin, Cetuximab, RT

Regimen

Chemotherapy

Targeted therapy

Radiotherapy

Capecitabine, Erlotinib, RT

Regimen

Chemotherapy

Targeted therapy

Radiotherapy

CarboMIP

CarboMIP: Carboplatin, Mitomycin, Ifosfamide, Platinol (Cisplatin)

Regimen

Chemotherapy

Carboplatin & Epirubicin

Regimen

Chemotherapy

Carboplatin & Paclitaxel (CP) & Bexarotene

CP & Bexarotene: Carboplatin, Paclitaxel, Bexarotene

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Cetuximab

CP & Cetuximab: Carboplatin, Paclitaxel, Cetuximab

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Erlotinib

CP & Erlotinib: Carboplatin, Paclitaxel, Erlotinib

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Pegylated liposomal doxorubicin

CP & PLD: Carboplatin, Paclitaxel, Pegylated Liposomal Doxorubicin
TC & PLD: Taxol (Paclitaxel), Carboplatin, Pegylated Liposomal Doxorubicin

Regimen

Chemotherapy

Carboplatin & Paclitaxel (CP) & Sorafenib

CP & Sorafenib: Carboplatin, Paclitaxel, Sorafenib

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Topotecan

TC & Topotecan: Taxol (Paclitaxel), Carboplatin, Topotecan

Regimen

Chemotherapy

Carboplatin & Topotecan

Regimen

Chemotherapy

CBM

CBM: Capecitabine, Bevacizumab, Mitomycin

Regimen

Chemotherapy

Targeted therapy

CCG

CCG: Cisplatin, Carboplatin, Gemcitabine

Regimen

Chemotherapy

Carboplatin & Etoposide (CE) & Ipilimumab

CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab

Regimen

Chemotherapy

Immunotherapy

Carboplatin & Etoposide (CE) & Thalidomide

CE & Thalidomide: Carboplatin, Etoposide, Thalidomide

Regimen

Chemotherapy

Targeted therapy

CIB

CIB: Cisplatin, Ifosfamide, Bleomycin

Regimen

Chemotherapy

Cisplatin & Methotrexate

Regimen

Chemotherapy

Cisplatin & Treosulfan

Regimen

Chemotherapy

Cisplatin & Vincristine

Regimen

Chemotherapy

Cisplatin, Avelumab, RT

Regimen

Chemotherapy

Immunotherapy

Radiotherapy

Cisplatin, Pemetrexed, RT

Regimen

Chemotherapy

Radiotherapy

CODE

CODE: Cisplatin, Oncovin (Vincristine), Doxorubicin, Etoposide

Regimen

Chemotherapy

CYVADIC

CYVADIC: CYclophosphamide, Vincristine, ADriamycin (Doxorubicin), Imidazole Carboxamide (Dacarbazine)

Regimen

Chemotherapy

DBCT

DBCT: Dacarbazine, BCNU (Carmustine), Cisplatin, Tamoxifen

Regimen

Chemotherapy

Endocrine therapy

Docetaxel & Gefitinib

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Pertuzumab

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Selumetinib

Regimen

Chemotherapy

Targeted therapy

Docetaxel & Sunitinib

Regimen

Chemotherapy

Targeted therapy

Docetaxel & ziv-Aflibercept

Regimen

Chemotherapy

Targeted therapy

Doxorubicin & Etoposide

Regimen

Chemotherapy

Doxorubicin & Paclitaxel

Regimen

Chemotherapy

Doxorubicin & Sorafenib

Regimen

Chemotherapy

Targeted therapy

Doxorubicin & Streptozocin

Regimen

Chemotherapy

Doxorubicin & Vinorelbine

Regimen

Chemotherapy

EAP

EAP: Etoposide, Adriamycin (Doxorubicin), Platinol (Cisplatin)

Regimen

Chemotherapy

ECVBP

ECVBP: Epirubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone

Regimen

Chemotherapy

Glucocorticoid therapy

EC-TL (Docetaxel)

EC-TL: Epirubicin & Cyclophosphamide, followed by Taxotere (Docetaxel) & Lapatinib
EC-DL: Epirubicin & Cyclophosphamide, followed by Docetaxel & Lapatinib

Protocol

Chemotherapy, EC portion

Chemotherapy, TL portion

Targeted therapy, TL portion

ELF

ELF: Etoposide, Leucovorin, 5-FU

Regimen

Chemotherapy

Encorafenib monotherapy

Regimen

Targeted therapy

EP & Ipilimumab

EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab

Regimen

Chemotherapy

Immunotherapy

EP, Tamoxifen, RT

EP, Tamoxifen, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy

Regimen

Chemotherapy

Endocrine therapy

Radiotherapy

Erlotinib & Sunitinib

Regimen

Targeted therapy

Everolimus & Vinorelbine

Regimen

Chemotherapy

Targeted therapy

E-GEMOX

E-GEMOX: Erlotinib, GEMcitabine, OXaliplatin

Regimen

Targeted therapy

Chemotherapy

FAP

FAP: Fluorouracil, Alfa interferon, Platinol (Cisplatin)

Regimen

Chemotherapy

Immunotherapy

FEC & HP

FEC & HP: Fluorouracil, Epirubicin, Cyclophosphamide, Herceptin (Trastuzumab), Pertuzumab

Regimen

Chemotherapy

Targeted therapy

FLA

FLA: FLudarabine & Ara-C (Cytarabine)

Regimen

Chemotherapy

FLAG-Ida & GO

FLAG-Ida & GO: FLudarabine, Ara-C (Cytarabine), G-CSF (Lenograstim), Idarubicin, Gemtuzumab Ozogamicin

Regimen

Chemotherapy

Growth factor therapy

Antibody-drug conjugate therapy

FLAI

FLAI: FLudarabine, Ara-C (Cytarabine), Idarubicin
FIA: Fludarabine, Idarubicin, Ara-C (Cytarabine)

Regimen

Chemotherapy

FOLF-CB

FOLF-CB: FOLinic acid, Fluorouracil, Cetuximab, Bevacizumab

Regimen

Chemotherapy

Targeted therapy

FOLFIRI & Regorafenib

FOLFIRI & Regorafenib: FOLinic acid, Fluorouracil, IRInotecan, Regorafenib

Regimen

Chemotherapy

Targeted therapy

FOLFIRI & Simvastatin

FOLFIRI & Simvastatin: FOLinic acid, Fluorouracil, IRInotecan, Simvastatin

Regimen

Chemotherapy

Targeted therapy

FOLFIRI & Sunitinib

FOLFIRI & Sunitinib: FOLinic acid, Fluorouracil, IRInotecan, Sunitinib

Regimen

Chemotherapy

Targeted therapy

FULV & Trimetrexate

FULV & Trimetrexate: 5-FU & LeucoVorin (Folinic acid), Trimetrexate

Regimen

Chemotherapy

GVP

GVP: Gemcitabine, Vinorelbine, Platinol (Cisplatin)

Regimen

Chemotherapy

ICE, ATRA, GO

ICE, ATRA: Idarubicin, Cytarabine, Etoposide, All-Trans Retinoic Acid, Gemtuzumab Ozogamicin

Regimen

Chemotherapy

Targeted therapy

Antibody-drug conjugate therapy

Ixabepilone & Bevacizumab

Regimen

Chemotherapy

Targeted therapy

ME

ME: Mitoxantrone & Etoposide

Regimen

Chemotherapy

MEV

MEV: Mitomycin, Etoposide, Vindesine

Regimen

Chemotherapy

MFL

MFL: Methyl-lomustine (MeCCNU), 5-FU, Leucovorin (Folinic acid)

Regimen

Chemotherapy

MFT

MFL: Methotrexate, 5-FU, Tamoxifen

Regimen

Chemotherapy

Endocrine therapy

Mitoxantrone & Hydrocortisone

Regimen

Chemotherapy

Endocrine therapy

MMF

MMF: Methyl-lomustine (MeCCNU), Mitomycin, 5-FU

Regimen

Chemotherapy

MPP

MPP: Melphalan, Prednisone, Procarbazine

Regimen

Chemotherapy

Glucocorticoid therapy

MTP

MTP: Myocet (Non-pegylated liposomal doxorubicin), Trastuzumab, Paclitaxel

Regimen

Chemotherapy

Targeted therapy

MVC

MVC: Mitomycin, Vindesine, Carboplatin

Regimen

Chemotherapy

NIP

NIP: Navelbine (Vinorelbine), Ifosfamide, Platinol (Cisplatin)

Regimen

Chemotherapy

PD & Pembrolizumab

PD & Pembrolizumab: Pomalidomide, Dexamethasone, Pembrolizumab

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Mateos et al. 2019 (KEYNOTE-183) 2016-2017 Phase 3 (E-esc) PD Seems to have inferior PFS
(HR 1.53, 95% CI 1.05-2.22)

Targeted therapy

Glucocorticoid therapy

Immunotherapy

PEI

PEI: Platinol (Cisplatin), Etoposide, Ifosfamide

Regimen

Chemotherapy

PELF

PELF: Platinol (Cisplatin), Epirubicin, Leucovorin, 5-FU

Regimen

Chemotherapy

PGT

PGT: Platinol (Cisplatin), Gemcitabine, Taxol (Paclitaxel)

Regimen

Chemotherapy

PGV

PGV: Platinol (Cisplatin), Gemcitabine, Vinorelbine
CGV: Cisplatin, Gemcitabine, Vinorelbine

Regimen

Chemotherapy

Pemetrexed & Cetuximab

Regimen

Chemotherapy

Targeted therapy

Pemetrexed & Vandetanib

Regimen

Chemotherapy

Targeted therapy

Pixantrone & Rituximab

Regimen

Chemotherapy

Targeted therapy

PVI

PVI: Platinol (Cisplatin), Vindesine, Ifosfamide
VIP: Vindesine, Ifosfamide, Platinol (Cisplatin)

Regimen

Chemotherapy

R-BEACOPP

R-BEACOPP: Rituximab, Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone

Regimen

Targeted therapy

Chemotherapy

Glucocorticoid therapy

R-MegaCHOEP

R-MegaCHOEP: Rituximab, high-dose (Mega) Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Etoposide, Prednisone

Targeted therapy

Chemotherapy

Glucocorticoid therapy

Realgar-Indigo naturalis formula monotherapy

Regimen

Targeted therapy

TCG

TCG: Taxol (Paclitaxel), Carboplatin, Gemcitabine

Regimen

Chemotherapy

TCHL (Docetaxel)

TCHL: Taxotere (Docetaxel), Carboplatin, Herceptin (Trastuzumab), Lapatinib

Regimen

Chemotherapy

Targeted therapy

TCL (Docetaxel)

TCL: Taxotere (Docetaxel), Carboplatin, Lapatinib

Regimen

Chemotherapy

Targeted therapy

TEC

TEC: Taxol (Paclitaxel), Epirubicin, Carboplatin

Regimen

Chemotherapy

Paclitaxel & Trastuzumab (TH) & Everolimus

TH & Everolimus: Taxol (Paclitaxel), Herceptin (Trastuzumab), Everolimus

Regimen

Chemotherapy

Targeted therapy

TPCV

TPCV: Thioguanine, Procarbazine, CCNU, Vincristine

Regimen

Chemotherapy

VADx

VADx: Vincristine, Ara-C (Cytarabine), Dexamethasone

Regimen

Chemotherapy

Glucocorticoid therapy

VAPEC-B

VAPEC-B: Vincristine, Adriamycin (Doxorubicin), Prednisolone, Etoposide, Cyclophosphamide, Bleomycin

Regimen

Chemotherapy

Glucocorticoid therapy

VBM (Vinblastine)

VBM: Vinblastine, Bleomycin, Methotrexate

Regimen

Chemotherapy

VCE

VCE: Vincristine, Carboplatin, Etoposide

Regimen

Chemotherapy

Vinorelbine & Hydrocortisone

Regimen

Chemotherapy

Endocrine therapy

VNC

VNC: Vincristine, Novantrone (Mitoxantrone), Cyclophosphamide

Regimen

Chemotherapy

VPV

VPV: Vinblastine, Platinol (Cisplatin), VP-16 (Etoposide)

Regimen

Chemotherapy

VTDC

VTDC: Velcade (Bortezomib), Thalidomide, Dexamethasone, Cyclophosphamide

Regimen

Targeted therapy

Glucocorticoid therapy

Chemotherapy

Regimens that contain experimental (unapproved) drugs

Adavosertib & Gemcitabine

Regimen

Targeted therapy

Chemotherapy

Alisertib monotherapy

Regimen

Targeted therapy

Amonafide & Cytarabine

Regimen

Chemotherapy

Buparlisib & Fulvestrant

Regimen

Targeted therapy

Endocrine therapy

Buparlisib & Paclitaxel

Regimen

Targeted therapy

Chemotherapy

Carboplatin & Paclitaxel (CP) & Cediranib

CP & Cediranib: Carboplatin, Paclitaxel, Cediranib

Regimen

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Trebananib

TC & Trebananib: Taxol (Paclitaxel), Carboplatin, Trebananib

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Vergote et al. 2019 (TRINOVA-3) 2012-2014 Phase 3 (E-esc) TC Did not meet primary endpoint of PFS
(HR 0.93, 95% CI 0.79-1.09)

Chemotherapy

Targeted therapy

Carboplatin & Paclitaxel (CP) & Veliparib

CP & Veliparib: Carboplatin, Paclitaxel, Veliparib

Regimen

Chemotherapy

Targeted therapy

Cediranib monotherapy

Regimen

Targeted therapy

Docetaxel & Bavituximab

Regimen

Chemotherapy

Immunotherapy

Docetaxel & Ganetespib

Regimen

Chemotherapy

Targeted therapy

Erlotinib & Figitumumab

Regimen

Targeted therapy

Erlotinib & Onartuzumab

Regimen

Targeted therapy

Erlotinib & Tivantinib

Regimen

Targeted therapy

Cisplatin & Gemcitabine (GC) & Veliparib

GC & Veliparib: Gemcitabine, Cisplatin, Veliparib

Regimen

Chemotherapy

Targeted therapy

Ibrutinib & Ublituximab

Regimen

Targeted therapy

Pegylated liposomal doxorubicin & Trebananib

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Marth et al. 2016 (TRINOVA-2) 2011-2013 Phase 3 (E-esc) PLD Did not meet primary endpoint of PFS
(HR 0.92, 95% CI 0.68-1.24)

Chemotherapy

Targeted therapy

Retrieved from "https://hemonc.org/w/index.php?title=Stub&oldid=62348"